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A B S T R A C TObjectives: To assess the expected costs and outcomes of alternative
strategies for staging of lung cancer to inform a Danish National
Health Service perspective about the most cost-effective strategy.
Methods: A decision tree was specified for patients with a confirmed
diagnosis of non–small-cell lung cancer. Six strategies were defined
from relevant combinations of mediastinoscopy, endoscopic or endobron-
chial ultrasound with needle aspiration, and combined positron emission
tomography-computed tomography with F18-fluorodeoxyglucose.
Patients without distant metastases and central or contralateral nodal
involvement (N2/N3) were considered to be candidates for surgical
resection. Diagnostic accuracies were informed from literature reviews,
prevalence and survival from the Danish Lung Cancer Registry, and
procedure costs from national average tariffs. All parameters were
specified probabilistically to determine the joint decision uncertainty.
The cost-effectiveness analysis was based on the net present value of
expected costs and life years accrued over a time horizon of 5 years.
Results: At threshold values of around h30,000 for cost-effectiveness, itsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2012.09.007
sdu.dk.
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f Southern Denmark, J.B. Winsløws Vej 9B, 5000 Owas found to be cost-effective to send all patients to positron emission
tomography-computed tomography with confirmation of positive find-
ings on nodal involvement by endobronchial ultrasound. This result
appeared robust in deterministic sensitivity analysis. The expected value
of perfect information was estimated at h52 per patient, indicating that
further research might be worthwhile. Conclusions: The policy recom-
mendation is to make combined positron emission tomography-
computed tomography and endobronchial ultrasound available for sup-
plemental staging of patients with non–small-cell lung cancer. The effects
of alternative strategies on patients’ quality of life, however, should be
examined in future studies.
Keywords: cost-effectiveness evaluation, decision analysis, diagnostic
radiology, health economic modeling, lung cancer, probabilistic
sensitivity analysis.
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Thoracotomy is the major potentially curative treatment in
non–small-cell lung cancer, although it is associated with a
mortality risk per se. Accurate staging of the disease to select
candidates with a reasonable chance of being cured is imperative
to increase the overall survival of this patient population.
The disease stage assessment is usually based on the Moun-
tain classification, which categorizes patients into seven stages
according to tumor size and location (T), nodal involvement (N),
and the presence of distant metastases (M), for which reason the
resulting categorization is also referred to as the TNM status [1].
The conventional modalities for staging include mediastino-
scopy, computed tomography (CT), and positron emission tomo-
graphy (PET) with F18-fluorodeoxyglucose. Each technology
demonstrates superior diagnostic accuracy in one or more of
the dimensions in the Mountain classification.In recent years, alternatives or supplements to the conventional
staging technologies have emerged and become part of clinical
practice in some centers due to their superior accuracy, less
disutility for the patient, and/or lower average costs. These alter-
natives include endoscopic ultrasound with fine needle aspiration
(EUS-FNA), endobronchial ultrasound with transbronchial needle
aspiration (EBUS-TBNA), and combined PET-CT with F18-
fluorodeoxyglucose. These modalities are described and imple-
mented in the European clinical guidelines, although a certain
degree of flexibility is expressed in terms of the exact type of test
that is appropriate, such as whether mediastinoscopy, EUS-FNA, or
EBUS-TBNA should be used to confirm PET findings [2].
The cost-effectiveness of the more recent modalities has not
been analyzed in a decision model. Sporadic evidence has begun
to emerge in the form of trial-based cost-effectiveness evalua-
tions based on intermediate outcomes, such as the number of
futile thoracotomies [3,4]. In a decision analytic context, thisSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
vices Research and Technology Assessment, Institute for Public
dense, Denmark.
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which are related to the fast pace of technology advancements
and methodological issues. First, there appear to be no studies
that include all relevant comparators. Second, the diagnostic
accuracies observed in a single trial may be problematic to
generalize as technologies mature and disseminate to settings
different from the early adaptors’. Third, the use of intermediate
outcome measures and/or the analysis of survival in small
samples by using only a limited time horizon render results
inconclusive. These controversies essentially disqualify the early
trial-based cost-effectiveness studies in a health policy decision-
making context.
The objective of this study was to model expected costs and
outcomes of alternative strategies for the staging and treatment
of lung cancer to inform a Danish National Health Service
perspective about the most cost-effective strategy.Methods
A probabilistic decision tree model was developed [5]. Full details
of the proposed model and the associated assumptions are given
in a technical report [6], but a summary is provided here.
Study Population
The model was defined for a patient with a histologically- or
cytologically verified diagnosis of non–small-cell lung cancer.
This specification applies when patients are not referred to a
specialized diagnostic center before they have a confirmed
diagnosis of lung cancer, typically based on clinical anamnesis,
chest X-ray, bronchoscopy and/or transthoracic biopsy, and CT,
and was considered fit for surgery. The typical patient is 65 years
old (man or woman).
Criteria for Operability
Patients who during staging workup were found without distant
metastases and without involvement of the central or contral-
ateral lymph nodes (N2/N3) were considered to be candidates for
treatment with curative intent, which mainly entails surgical
resection.
Choice of Comparators
Specialized staging may use one or more of the following
modalities: mediastinoscopy, EUS-FNA, EBUS-TBNA, and com-
bined PET-CT with F18-fluorodeoxyglucose. The three former
modalities are relatively accurate in assessing nodal involvement
(N status) but cannot assess the presence/absence of distant
metastases (M status). The latter modality is able to assess both
dimensions, but suffers from poorer accuracy in the assessment
of N status, for which reason positive findings should be con-
firmed [2]. Altogether, these comparators create four relevant
strategies. Two additional strategies were defined to address
more speculative hypotheses: 1) the initial CT might become
redundant when PET-CT is applied and 2) confirming all nodal
findings (not just the positive findings) after PET-CT might be
worthwhile for the prevention of futile thoracotomies. The
strategies were defined as follows:A. Patients with distant metastases at the initial CT are referred
directly to nonsurgical treatment. All others are referred to
mediastinoscopy. Patients without nodal involvement are
referred to thoracotomy, and patients with nodal involvement
are referred to nonsurgical management.B. Identical to strategy A except that mediastinoscopy is
replaced by EUS-FNA.C. Identical to strategy A except that mediastinoscopy is
replaced by EBUS-TBNA.D. Patients with distant metastases at the initial CT are referred
directly to nonsurgical treatment. All others are referred to
PET-CT. In the case of upstaging due to distant metastases, the
patient is referred to nonsurgical management. If not, the PET-
CT results on nodal involvement determine the pathway;
patients without nodal involvement are referred directly to
thoracotomy, and patients with nodal involvement are
referred to a conclusive EBUS-TBNA.E. Identical to strategy D except that the initial CT is excluded.
F. Identical to strategy D except that all patients (not just those
testing positive) have their PET-CT results on nodal status
confirmed.
As strategies A to C all include a primary CT scan and no PET-
CT scan, they are intended to contrast the performance of
different modalities for mediastinal staging. Based on the com-
parative outcomes of these strategies (which will appear from the
following analysis) plus the fact that it is widely used in clinical
practice, the EBUS-TBNA was chosen as the modality for med-
iastinal staging in the three latter strategies. Holding this con-
stant, strategies D to F thus contrast different ways of
implementing PET-CT.
Model Structure and Assumptions
The proposed model is illustrated in Figure 1 and imposes a
number of structural assumptions. First, it assumes that the
N-status results of radiology-based tests are disregarded once an
invasive test has been performed. This assumption has the
largest impact on PET-based strategies, where diagnostic accu-
racy might be marginally underestimated. Second, it assumes
that there is no morbidity or mortality risk associated with the
tests, which could favor invasive modalities. Third, it assumes
that relapse does not occur after successful thoracotomy, which
could lead to an underestimation of costs for the thoracotomy
arms (whereas survival is inclusive of relapse). Fourth, the model
structure does not include the costs of any ad hoc tests. Most
centers will confirm, for example, M1 findings on the initial CT or
PET-CT by using magnetic resonance or ultrasonography before
excluding the patient from potentially curative treatment. This
assumption could bias the results against strategies A, B, and C,
where fewer tests are included in the strategies and more
supplemental tests are therefore likely to be appended. Finally,
and perhaps most importantly, the choice of a decision tree
model implies that the passing of time is not explicit, which may
affect results in an uncertain direction depending on differences,
apart from survival and costs of understaging, between strategies
over the course of the defined time period.
Model Population
Tables 1 and 2 present the parameter estimates used to inform
the decision model, the sources of the parameter estimates, and
how they were specified for the probabilistic sensitivity analysis.
These are commented on in the following sections.True disease distribution
It was assumed that the prevalence of N- and M-positives in the
Danish Lung Cancer Registry would represent true disease
distributions. All patients with a valid TNM status who were
diagnosed between 2003 and 2009 were included in the estimates
(n ¼ 16,874) [17]. As prevalence follows a continuous distribution
bounded by 0 and 1, it was specified according to the beta
distribution for the probabilistic analysis.
Fig. 1 – Decision tree model of alternative strategies for the staging and treatment of lung cancer. CT, computed tomography;
EBUS-TBNA, endobronchial ultrasound with transbronchial needle aspiration; EUS-FNA, endoscopic ultrasound with fine
needle aspiration; M, absence/presence of distant metastases (0/1); N, N stage according to the Mountain classification;
PET-CT, combined positron emission tomography and CT.
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Test accuracies of mediastinoscopy, EUS-FNA, and EBUS-TBNA
were obtained from recent systematic literature reviews [7–9].
Similar meta-analyses were not available for radiology-based
tests, and the original literature was found to demonstrate poor
between-study convergent validity in terms of how tests were
applied (e.g., anatomical focus) and the specified dimensions and
cut-off points (the model specified N0 vs. N1/2/3 dichotomiza-
tion). Upon assessment of the literature, seven original studies
were found to provide parameter estimates in a relevant format
for radiology-based tests [10–16]. Following the arguments given
for prevalence, diagnostic accuracies were specified according to
the beta distribution.
Survival
Mean survival in a 5-year time range from the first diagnostic test
was estimated from the Danish Lung Cancer Registry with
relevant strata according to the true disease distribution and
the treatment modality received. The probability of mortality
within 30 days after thoracotomy was estimated from the Danish
Lung Cancer Registry and assumed to be constant across all
thoracotomies (i.e., independent of disease status and diagnostic
history). In relation to the specification of probability distribution,
it should be noted that survival is always positive and expected to
follow a continuous distribution that is skewed with a tale to the
right. Several distributions reflect such characteristics, and some
of the commonly used are gamma and lognormal distributions.The optimal choice between these was examined in empirical
data [17], and the gamma distribution was chosen because of
demonstrating the best fit.Costs
The overall approach for costing was based on incidence costs in
the secondary health care sector [18], meaning that only costs of
diagnostics and treatment were included. National average tariffs
of the diagnosis-related group case-mix system were adapted.
SDs corresponding to 10% of the mean estimates for diagnostic
tests and 25% of the mean estimates for treatments were
assumed because the case-mix system does not provide precise
estimates. The treatment modalities included were based on the
current Danish and European recommendations. For patients
who were inoperable because of central or contralateral nodal
involvement (but no distant metastases), it was assumed that
chemotherapy and radiotherapy with at least 30 fractions were
administered [19,20]. For patients who were inoperable because
of distant metastases, it was assumed that only chemotherapy
was administered [21,22]. It was assumed that patients who
underwent thoracotomy despite unknown distant metastases
would receive additional nonsurgical management at some point
during postoperative follow-up [21]. Costs were specified to
follow a gamma distribution with reference to the same argu-
ments that were provided for the choice of this distribution to
reflect survival.
Table 1 – Parameter estimates for disease distribution and diagnostic test performances.
Parameter Source† Estimate Distributionz
Prevalence M1 DLCR 0.4807 Beta (16,874; 8,112)
Prevalence N1/2/3 DLCR
Conditional on M0 0.4627 Beta (8,402; 3,888)
Conditional on M1 0.7851 Beta (7,041; 5,528)
Prevalence N2/3 DLCR
Conditional on M0 0.3849 Beta (8,402; 3,234)
Conditional on M1 0.7117 Beta (7,041; 5,011)
Conditional on M0 and N1/2/3 0.8318 Beta (3,888; 3,234)
Conditional on M1 and N1/2/3 0.9065 Beta (5,528; 5,011)
Mediastinoscopy (N2/3 vs. N0/1) Detterbeck et al. [7]
Sensitivity 0.78 Beta (6,505; 5,074)
Specificity 1.00 Beta (6,505; 6,504)
EUS-FNA (N2/3 vs. N0/1) Puli et al. [8]
Sensitivity 0.88 Beta (2,680; 2,358)
Specificity 0.96 Beta (2,680; 2,573)
EBUS-TBNA (N2/3 vs. N0/1) Gu et al. [9]
Sensitivity 0.93 Beta (2,680; 2,492)
Specificity 1.00 Beta (2,680; 2,679)
CT (M1 vs. M0) Herder et al. [10]
Sensitivity 0.80 Beta (465; 372)
Specificity 1.00 Beta (465; 464)
PET-CT (N1/2/3 vs. N0)
Sensitivity Reed et al. [11] 0.75 Beta (574; 431)
Cerfolio et al. [12]
Halpern et al. [13]
De Wever et al. [14]
Yang et al. [15]
Specificity Same as above 0.78 Beta (574; 448)
PET-CT (M1 vs. M0)
Sensitivity Cerfolio et al. [12] 0.92 Beta (129; 119)
Specificity Fischer et al. [16] 0.98 Beta (189; 185)
30-day mortality thoracotomy DLCR 0.039 Beta (6,406; 250)
CT, computed tomography; DLCR, Danish Lung Cancer Registry; M, absence/presence of distant metastases (0/1); N, N stage according to the
Mountain classification; EBUS-TBNA, endobronchial ultrasound with transbronchial needle aspiration; EUS-FNA, endoscopic ultrasound with
fine needle aspiration; PET-CT ¼ combined positron emission tomography and CT.
* Prevalent cases according to N status do not sum to N ¼ 16,874 because of missing data on N status for some patients.
† Where more than one source appears, the results of the listed studies were pooled.
z The integer form of the beta distribution was used, i.e., beta(n,r) where n is the sample size and r is the number of events.
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The model was first tested by using relevant logical checks. For
example, test accuracies were set to 1.00, in which case there
should be no false positives and no false negatives. Second,
model predictions of intermediate outcomes were recorded for
the assessment of logical consistency across strategies
(see Table 3). Third, model predictions of key events and ultimate
outcomes were compared with observed events in a clinical trial
[16] for a qualitative assessment of agreement between the two.
The comparison could be made only for the strategies of
mediastinoscopy (strategy A) and PET-CT (strategy D), as the trial
did not include further comparators. Some divergence was
observed during the comparison of trial observations with model
predictions, but this could be explained by differences in study
populations and the extent to which the specified strategy was
adhered to in the analytic setting. Obviously, the model reflects a
simplified but also perfectly controlled scenario that did not
allow for ad hoc tests in addition to the specified strategies
whereas supplemental tests were commonly administered in the
trial. For example, 36% of the patients had supplemental endo-
scopic ultrasound and 7% had supplemental ultrasonography of
the abdomen. Concerning the study populations, it was notedthat the model population was characterized by a higher pre-
valence of distant metastases, which led to fewer events of
thoracotomy.Cost-Effectiveness Evaluation
The health economic evaluation adopted a secondary health care
sector perspective with a time period of 5 years. All monetary
estimates were inflated to 2010 euros by using the general
consumer price index when relevant. Discounting at 3% per year
was applied to represent the net present value of costs and
life years.
All parameter estimates were specified probabilistically. A
Monte Carlo simulation was used to make 10,000 independent
draws from the input distributions, each producing a set of
parameter estimates, to summarize the expected costs and life
years per strategy. The reported SDs are based on a 5% signifi-
cance level and represent the combined uncertainty of all input
parameters. Deterministic sensitivity analysis was used to test
the influence of alternative assumptions.
The final results were summarized in cost-effectiveness
acceptability curves illustrating the probability of a strategy being
Table 2 – Parameter estimates for survival and costs (in 2010h).
Parameter Source Estimate Distribution†
Survival (life years) DLCR
M0, N0/1 nonsurgical regimen 1.2359 Gamma (0.8002; 0.6475)
M0, N0/1 thoracotomy 2.9216 Gamma (2.2880; 0.7831)
M0, N2/3 1.0740 Gamma (0.8173; 0.7610)
M1 0.6440 Gamma (0.6551; 1.0163)
Postoperative mortality 0.1429 Gamma (5.0643; 35.4395)
Costs (h) Case-mix tariffs
Mediastinoscopy 6,159 Gamma (99.9675; 0.0162)
EUS-FNA 4,373 Gamma (100.1373; 0.0229)
EBUS-TBNA 5,220 Gamma (100.0000; 0.0192)
CT 294 Gamma (102.7776; 0.3496)
PET-CT 1,494 Gamma (100.5376; 0.0673)
Thoracotomy 7,620 Gamma (15.9952; 0.0012)
Nonsurgical regimen for M0 20,423 Gamma (15.9984; 0.0008)
Nonsurgical regimen for M1 12,908 Gamma (15.0526; 0.0012)
CT, computed tomography; DLCR, Danish Lung Cancer Registry; M, absence/presence of distant metastases (0/1); N, N stage according to the
Mountain classification; EBUS-TBNA, endobronchial ultrasound with transbronchial needle aspiration; EUS-FNA, endoscopic ultrasound with
fine needle aspiration; PET-CT, combined positron emission tomography and CT.
* Nonsurgical regimens included standard chemotherapy (cisplatin þ vinorelbine on day 1 and vinorelbine alone on day 8 in four cycles) for
M1 and standard chemotherapy þ at least 30 fractions of radiotherapy for M0.
† The gamma distribution is specified by gamma(a,l) where a refers to the shape of the distribution (in some cases approximated by mean2/
SE2) and l to the scale of the distribution (in some cases approximated by mean/SE2).
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ness to pay per life year [23,24]. The threshold is not explicit in
most health care systems, but the National Institute for Health
and Clinical Excellence in the United Kingdom has suggested a
threshold at about £20,000 to £30,000 [25]. A threshold of h30,000
was thus used as a reference point.
Value of Information Analysis
Expected value of perfect information analysis was conducted to
estimate the economic value of the uncertainty associated with
the choice between the alternative diagnostic strategies [26].
Based on the assumed threshold of h30,000 per life year, the
analysis provides a monetary value of a wrong decision that
could be made as a consequence of decision uncertainty. If that
value is greater than the costs associated with conducting more
research to eliminate uncertainty, it will be rational from anTable 3 – Accuracy of the modeled staging strategies.
Perfect accuracy
A
Thoracotomies 32 41
Nonfutile 32 31
Futile 0 10
Correctly classified
Presence of metastases 100 90
Nodal involvement 100 90
NA, not applicable; strategy A, send all patients to mediastinoscopy; str
aspiration (EUS-FNA); strategy C, send all patients to endobronchial ultr
D, send all patients to combined positron emission tomography and com
central or contralateral nodal involvement by EBUS-TBNA; strategy E, s
strategy D except that negative findings on central or contralateral noda
Estimates are adjusted for the fact that patients who were found to have
contralateral nodal involvement.
* Values are predicted number of events per 100 patients.economic perspective to invest in more research. It should be
noted however that the estimate represents a maximum value
and that further research is unlikely to completely eliminate
decision uncertainty.Results
The expected costs and outcomes of the strategies are shown in
Table 4. The strategy of sending all patients to PET-CT followed by
the confirmation of positive findings on central or contralateral
nodal involvement (strategy D) appeared to be the least costly,
whereas the simpler strategy of using only mediastinoscopy for
staging (strategy A) appeared to be the most costly. Two cost
drivers explained this result: the cost of mediastinoscopy, which
is more than four times as high as the cost of PET-CT, and the
number of patients who underwent a futile thoracotomy, whichStrategy
B C D E F
36 37 37 39 33
29 31 30 30 30
7 6 7 9 3
90 90 98 95 98
92 97 88 87 98
ategy B, send all patients to endoscopic ultrasound with fine needle
asound with transbronchial needle aspiration (EBUS-TBNA); strategy
puted tomography (PET-CT) with confirmation of positive findings on
imilar to strategy D but without the initial CT; strategy F, similar to
l involvement are also confirmed by EBUS-TBNA.
distant metastases at the first test were not evaluated for central or
Table 4 – Expected costs and outcomes per patient of the
modeled strategies.
Strategy Mean  SD
Cost (h) Life years
A: Mediastinoscopy 20,803  2,512 1.291  0.612
B: EUS-FNA 19,607  2,482 1.275  0.599
C: EBUS-TBNA 19,933  2,459 1.292  0.612
D: PET-CT 18,067  2,319 1.282  0.605
E: PET-CT excluding initial CT 18,562  2,415 1.283  0.606
F: PET-CT þ EBUS-TBNA 18,616  2,254 1.284  0.606
CT, computed tomography; EBUS-TBNA, endobronchial ultrasound
with transbronchial needle aspiration; EUS-FNA, endoscopic ultra-
sound with fine needle aspiration; PET-CT, combined positron
emission tomography and CT.
Fig. 3 – Cost-effectiveness acceptability curves.
Note. Individual curves represent the probability that a
strategy will be cost-effective for threshold values of
decision-makers’ willingness to pay per life year. At
conventional threshold levels of approximately h30,000,
strategy D (where patients with PET-CT-positive N1/N2/N3
lymph nodes undergo confirmatory EBUS-TBNA) appeared
to be the most likely to be cost-effective, with a probability
of 0 .75. EBUS-TBNA, endobronchial ultrasound with
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outcomes, the strategy of sending all patients to EBUS-TBNA
(strategy C) appeared to be the most attractive, with an average
gain of 1.292 life years, whereas sending all patients to EUS-FNA
(strategy B) resulted in the least attractive average life-year gain
of 1.275. Outcome differences between strategies were moderate
because none of the strategies were able to identify all patients
with a true indication for thoracotomy and because the differ-
ences across strategies in terms of the number of futile thoraco-
tomies (shown in Table 3) had little effect in terms of survival.
Considering both expected costs and life years, two strategies
dominated the others. Figure 2 illustrates how a rational choiceFig. 2 – The cost-effectiveness plane for alternative
strategies.
Note. The connecting line between strategies D, E, and C
illustrates the expansion path, whereas the slope expresses
the extra costs per life-year gain: h149,249 for moving from
strategy D to E (sending patients directly to PET-CT without
initial CT) and h233,648 for moving from strategy E to C
(sending all patients directly to EBUS-TBNA). Dominated
strategies are those that offer fewer life years at higher costs
compared with nondominated strategies. EBUS-TBNA,
endobronchial ultrasound with transbronchial needle
aspiration; PET-CT, combined positron emission
tomography (PET) and computed tomography (CT).
transbronchial needle aspiration; PET-CT, combined
positron emission tomography and computed
tomography (CT).stands between sending all patients to PET-CTwith confirmation of
positive findings on central or contralateral nodal involvement by
EBUS-TBNA (strategy D) and sending some or all patients directly
to the more costly strategy, EBUS-TBNA (strategy C). The incre-
mental cost-effectiveness ratio associated with moving from strat-
egy D to strategy C was estimated at h188,461 per life year. The
dominated strategies include sending all patients to mediastino-
scopy (strategy A) and sending all patients to EUS-FNA (strategy B),
as these strategies provide poorer outcomes at higher costs than do
alternative strategies. The two remainder strategies, sending
patients directly to PET-CT without preceding CT (strategy E) and
sending all patients to EBUS-TBNA after PET-CT (strategy F),
provide life-year gains that can be achieved at lower costs by a
mix of alternative strategies. This is usually referred to as extended
dominance and can be illustrated by an example of a scenario with
1000 new cases of lung cancer, say. Sending all patients to EBUS-
TBNA after PET-CT (strategy F) would result in 1284 life years and
cost h18.6 million, whereas sending 200 to EBUS-TBNA (strategy C)
and 800 to PET-CT (strategy D) would result in the same life-year
gain, only at a lower cost (h18.4 million).
Figure 3 illustrates the probabilities that individual strategies
will be cost-effective given the combined decision uncertainty of
all input parameters of the model. For a threshold value of
h30,000, the least costly strategy (strategy D) appeared to be
cost-effective with a probability of 0.80. Alternative scenario
analysis confirmed the high probability for this strategy being
the optimal choice, as the competing strategies were, in all
scenarios, associated with very high incremental cost-
effectiveness ratios (see Table 5).
Any deviation from a probability of 1.0 for cost-effectiveness
indicates decision uncertainty. The expected value of perfect
information analysis essentially assesses the economic value or
Table 5 – Alternative scenario analysis: Results for nondominated strategies.
Probability cost-effective at given threshold (h)
Average costs (h) Average life years ICER 15,000 30,000 45,000
Base-case analysis
D: PET-CT 18,067 1.282 NA 0.85 0.80 0.73
C: EBUS-TBNA 19,933 1.292 188,461 0.00 0.02 0.05
Alternative scenario 1: 5% lower prevalence of distant metastases
D: PET-CT 18,262 1.313 NA 0.80 0.75 0.68
C: EBUS-TBNA 20,030 1.323 169,807 0.00 0.03 0.07
Alternative scenario 2: 5% poorer test performance of PET-CT
D: PET-CT 18,038 1.263 NA 0.81 0.64 0.50
C: EBUS-TBNA 19,905 1.294 61,323 0.04 0.21 0.36
Alternative scenario 3: all survival quality adjusted by a factor 0.70
D: PET-CT 18,090 0.900 NA 0.84 0.79 0.73
C: EBUS-TBNA 19,952 0.904 267,199 0.00 0.01 0.04
Alternative scenario 4: 20% higher costs of PET-CT
D: PET-CT 18,236 1.282 NA 0.88 0.82 0.75
C: EBUS-TBNA 19,917 1.291 170,266 0.00 0.03 0.08
EBUS-TBNA, endobronchial ultrasound with transbronchial needle aspiration; ICER, incremental cost-effectiveness ratio; PET-CT, combined
positron emission tomography and computed tomography (CT).
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 7 – 6 5 63consequence of a wrong decision, which will indicate whether
further research is cost-effective. At a threshold value of h30,000,
the expected value of perfect information was estimated at h52
per patient. In other words, if decision makers are willing to pay
30,000h per life year, it would be cost-effective to invest in
additional research of a value of up to h52 per new case of lung
cancer rather than risking a nonoptimal decision about the
recommended strategy for staging; for example, for a target
population of 4000 new cases per year, assuming the decision
scenario holds relevance for a 5-year period, the benefit of
additional research that could eliminate decision uncertainty is
about h1 million (undiscounted).Discussion
This study proposes a decision analytic model for a scenario that
is complex due to the richness of available diagnostic
modalities—some of which are substitutes, whereas others are
more supplemental—and the three-dimensional staging algo-
rithm used in clinical practice.
Four of the six strategies assessed appeared to be dominated
by others. Consequently, only two strategies were identified to be
potentially cost-effective: sending patients to PET-CT with con-
firmation of positive findings on central or contralateral nodal
involvement by EBUS-TBNA (strategy D) and the more costly
strategy of sending patients directly to EBUS-TBNA (strategy C).
At a threshold level of h30,000, strategy D was found to be
cost-effective with a probability of 0.80 due to a very high
incremental cost-effectiveness ratio of the competing alternative.
This finding actually supports the current European Society of
Thoracic Surgeons and The American College of Chest Physicians
clinical guidelines, as the strategy is very close to their recom-
mendations [2,7]. It should be stressed, however, that strategy D
was not the most accurate, especially with regard to lymph node
staging. Had we been able to discern between central and
peripheral tumors in our modeling setup, it would most likely
have increased both accuracy and costs associated with strategy
D, but it seems unlikely that this would be to an extent that
would weaken the conclusion. With regard to strategy E, our
analysis relied on similar performance of PET-CT with regard to
N- and M-staging, as in a population initially screened by CT.Data on the performance of upfront PET-CT in this setting are
scarce, but findings by Herder et al. [10] on upfront PET versus
conventional workup indicate that the specificity is unchanged or
slightly better whereas sensitivity seems to be lower. Had we
used their estimates to describe upfront PET-CT it would have led
to poorer outcomes of strategy E (more patients with nodal
involvement would have been overlooked whereas positive find-
ings would have been retested by EBUS-TBNA) and eventually
strengthened the conclusion about this strategy not being cost-
effective. Most other reports of PET-CT and CT are the result of an
intraindividual comparison and even though the positive and
negative predictive values might change with the patient popula-
tion, the sensitivity and specificity should remain relatively
constant. Thus, we find it reasonable to use the same estimates
for PET-CTwhether administered upfront or following CT.Comparison with Other Studies
There are no other studies against which meaningful compar-
isons can be made because the previous modeling studies do not
include the more recent modalities of combined PET-CT and
EBUS-TBNA.
Several studies have been published that compare the conven-
tional strategies of mediastinoscopy and stand-alone PET. Of
European origin alone, at least five studies have been reported
[27–31]. Three of these studies agreed that PETwas a cost-effective
adjunct to a conventional workup when applied under a strategy
with the confirmation of positive findings on central or contral-
ateral involvement by mediastinoscopy [27–29]. These results can
be seen as a first-generation analogue to the present findings,
where more recent technologies have replaced older ones— com-
bined PET-CT have replaced PET and EBUS-TBNA have replaced
mediastinoscopy—but the results lead to similar conclusions.Strengths and Limitations
This study is the first to include some of the more recent
diagnostic technologies, such as EBUS-TBNA and combined
PET-CT, in a decision model. It is also the first to report
probabilistic sensitivity analysis within the area of lung cancer
staging.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 7 – 6 564Prevalence and survival parameters were informed from the
Danish Registry for Lung Cancer, which represents a large and
well-characterized population (420,000 patients) of recent cases
staged and treated by modern modalities. An additional strength
of the study is that the evaluated strategies are very close to the
recommendations of both the European and the American
societies for lung cancer staging, and to clinical practice in
Denmark [2,32].
The costing perspective was limited to procedure costs of
diagnostic tests and the indicated therapeutic treatment. The
relevance of a broader costing perspective has been investigated
in a trial-based cost-effectiveness evaluation that also analyzed
register data on primary care, other secondary care, and pre-
scription medication for 189 patients who were included in a
randomized controlled trial comparing conventional staging to
PET-CT–based staging [4]. It was confirmed that the tradition of
not including these cost categories is still appropriate. The usual
disclaimer about unit costs not being generalizable across set-
tings does, however, still apply.
The most important limitations of the study relate to the
estimates of test accuracies and the fact that no quality-of-life
adjustment was made. The strategy for informing parameters of
test accuracies was to adapt results of systematic literature
reviews and meta-analyses. These were not available for
radiology-based tests, and so the literature was searched and
assessed for any usable estimates. This search was not done in a
strictly systematic manner, and estimates were pooled without
formal quality assessment of the included original studies. The
variation in results furthermore indicated that diagnostic accu-
racy might vary across settings, but because no institutional or
cultural details were generally provided by reports, it was not
possible to examine this concept further.
We conducted sensitivity analysis by quality adjusting all
survival, and it appeared to only strengthen the conclusion. If,
however, different temporary quality-of-life effects are asso-
ciated with undergoing different staging strategies, it could affect
results in an uncertain direction. The patient’s quality of life may
be significantly reduced while awaiting the surgery, by being
informed that surgery was futile, and by the physical stress the
surgery imposes at a time when the patient is particularly
vulnerable. A systematic literature search was conducted to
identify estimates of utility weights that related to the staging
strategies, but only sporadic estimates relating primarily to
chemotherapy were found [6]. The identified estimates varied to
such an extent that making assumptions about all tests and
treatments in the model seemed unreasonable.
The organization of diagnostics varies in different settings.
In particular, there seem to be two relevant choices of study
population depending on whether diagnostics and staging are
seen as integrated or separate regimens. In some health care
systems, the patient is referred directly to centers specialized in
diagnosis and eventual staging upon indices of lung cancer (e.g., a
solitary pulmonary node). In other health care systems, the patient
is not referred to specialized centers before he or she has a
histologically- or cytologically verified diagnosis. The modeling
literature has traditionally used the latter definition of study popula-
tions, and the present model also follows this definition. It will be
interesting for future studies to adopt the alternative definition
because it is increasingly seen in clinical studies and may represent
a more modern approach for rapid, specialized diagnostics.Conclusions
The recommendation for National Health Service policy making
in Denmark is to make combined PET-CT and EBUS-TBNA avail-
able for the staging of patients with non–small-cell lung cancer.The impact of staging strategies on patients’ quality of life,
however, remains an unresolved issue for future studies.Acknowledgments
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